Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion JIANGSU, China, July 27, 2025 /PRNewswire/ — Hengrui Pharma…
